TLK-286

IDrugs. 2004 Aug;7(8):771-81.

Abstract

Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic / trends
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / pharmacokinetics
  • Drugs, Investigational / therapeutic use*
  • Glutathione / analogs & derivatives*
  • Glutathione / chemistry
  • Glutathione / pharmacokinetics
  • Glutathione / therapeutic use*
  • Humans
  • Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • TER 286
  • Glutathione